

Efficacy Trial

2017

2018

2019

2020



HOPE (MTN 025)

Open-label trial of the once-monthly slow-release dapivirine vaginal ring; ongoing in 2,500 women in Malawi, South Africa, Uganda, Zimbabwe

DREAM (IPM 032)

Open-label trial of the once-monthly slow-release dapivirine vaginal ring; ongoing in 1,400 women in South Africa and Uganda



AMP (HVTN 704/ HPTN 085)

Randomized controlled trial of the VRC01 antibody infused every two months; ongoing in 2,700 MSM and transgender persons in Brazil, Peru, Switzerland and US

AMP (HVTN 703/ HPTN 081)

Randomized controlled trial of the VRC01 antibody infused every two months; ongoing in 1,500 women in Botswana, Kenya, Malawi, Mozambique, Tanzania, South Africa, Zimbabwe



DISCOVER

Randomized controlled trial of once-daily F/TAF as PrEP; ongoing in 5,000 MSM and transgender women at approximately 90 sites in Europe and the Americas



HPTN 083

Randomized controlled trial of injectable cabotegravir every two months; ongoing in 4500 MSM and transgender persons in Argentina, Brazil, India, Peru, South Africa, Thailand, US, Vietnam

HPTN 084

Randomized unblinded trial of injectable cabotegravir every two months; planned for women in Southern and East African countries



ALVAC/gp120 w/MF59

HVTN 702

Randomized controlled trial of ALVAC/gp120 prime-boost with MF59 adjuvant, five doses over 12 months; ongoing in 5,400 men and women in South Africa

Ad26/MVA boost

HVTN 705/HPX2008

Randomized controlled trial of Ad26 prime and MVA boost; planned for men and women in the Americas and Southern and East Africa